GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
A

argenx ARGX.BR · EUR

Health Care · Biotechnology · Euronext Brussels · 🇧🇪 Belgium

Euro Stoxx 50

Compare

853.80

+4.66%

Close of 9 Nov 2026, in EUR

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Price performance

Chart by TradingView, with its own licensed prices

argenx — daily ARGX

No embeddable chart for this listing. TradingView's free widgets do not cover this exchange, and an unsupported symbol would render an error panel rather than a chart.

View argenx on TradingView ↗
Market value
€53.10bn
Last close × shares
Volume
108.2k
Shares, 9 Nov 2026
Price to earnings
53.8

About argenx

Its shares trade on Euronext Brussels under the ticker ARGX.BR. It has been listed since 10 July 2014. It is a member of the Euro Stoxx 50. In the fiscal year to 31 December 2025, it reported revenue of $3.60bn and net income of $1.12bn. At that date it held total assets of $7.52bn and shareholders' equity of $6.35bn.

argenx SE is a clinical-stage biotechnology company, which engages in the development of antibody-based therapies for the treatment of autoimmune diseases and cancer. The company is headquartered in Breda, Noord-Brabant. The company went IPO on 2014-07-10. The company creates and develops a pipeline of differentiated antibody therapeutics using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The firm develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. The company includes: ARGX-110, an antibody for heme malignancies and solid tumors, which modulates functions of tumor such as cell proliferation and survival; ARGX-111, an antagonist of c-Met, a receptor tyrosine kinase involved in cell proliferation, angiogenesis and metastasis in multiple solid tumors; ARGX-112, an antigen which targets atopic dermatitis by neutralization of IL-20 and IL-22 (interleukin) mediated signaling through blockade of their common receptor, among others.

Figures and description from our data supplier, not checked against the company's own report.

More about argenx →

Latest on argenx

Our reporting

Next results

25 Feb 2027

Due on 25 Feb 2027. Analysts expect earnings of 8.25 a share.

Other Health Care listings

Scenario calculator

Try your own numbers. This is arithmetic, not a forecast.

Interactive

Gain or loss

—

Return

—

Leaves out fees, taxes and financing.

Frequently asked questions

What is argenx's ticker?

argenx trades as ARGX.BR on Euronext Brussels, under ISIN NL0010832176.

What was argenx's last closing price?

853.80 on 9 Nov 2026. The figure is in EUR and is never converted.

When does argenx next report results?

Results are expected on 25 Feb 2027, according to our data supplier.

Sources and methodology

Chart
TradingView
Close and company data
Our data supplier
News
Our reporting

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.